ASH 2022 | Phase II trial of inotuzumab ozogamicin to treat MRD+ B-ALL
Jayastu Senapati
• 11 Dec 2022
Jayastu Senapati, MBBS, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an update on a Phase II trial (NCT03441061) assessing the efficacy of inotuzumab ozogamicin in eradicating measurable residual disease (MRD) in patients with B-cell acute lymphoblastic leukemia (B-ALL). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
